Bone marrow-derived microglia-based neurturin delivery protects against dopaminergic neurodegeneration in a mouse model of Parkinson's disease

Neuroscience Letters

Volumn 535, Issue 1, 2013, Pages 24-29

  Biju, K C ^a   Santacruz, Rene A ^a   Chen, Cang ^a   Zhou, Qing ^a   Yao, Jiemin ^a   Rohrabaugh, Sara L ^a   Clark, Robert A ^a,c   Roberts, James L ^b,c,d   Phillips, Kimberley A ^d   Imam, Syed Z ^e   Li, Senlin ^a,b,c  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^d TRINITY UNIVERSITY   (United States)

^e CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Dopamine; Gene therapy; Neurodegenerative disease; Neurotrophic factors; Parkinson's disease

Indexed keywords

GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; NEURTURIN; SYNAPTOPHYSIN;

ALLODYNIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BODY WEIGHT; BONE MARROW CELL; CONTROLLED STUDY; CYTOPLASM; DRUG DELIVERY SYSTEM; EX VIVO STUDY; GENE THERAPY; LOCOMOTION; MALE; MICROGLIA; MOTOR DYSFUNCTION; MOUSE; NERVE DEGENERATION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; STEM CELL GENE THERAPY; SUBSTANTIA NIGRA PARS COMPACTA; SUBSTANTIA NIGRA PARS RETICULATA; WHOLE BODY RADIATION;

ANIMALS; BONE MARROW CELLS; BONE MARROW TRANSPLANTATION; BRAIN; DOPAMINERGIC NEURONS; GENETIC THERAPY; LENTIVIRUS; MALE; MAZE LEARNING; MICE; MICE, INBRED C57BL; MICROGLIA; MOTOR ACTIVITY; NERVE DEGENERATION; NEURTURIN; PARKINSON DISEASE;

EID: 84873256816     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2012.12.034     Document Type: Article

References (23)

1. Bernheimer H., Birkmayer W., Hornykiewicz O., Jellinger K., Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. Journal of the Neurological Sciences 1973, 20:415-455.
2. Biju K., Zhou Q., Li G., Imam S.Z., Roberts J.L., Morgan W.W., Clark R.A., Li S. Macrophage-mediated GDNF delivery protects against dopaminergic neurodegeneration: a therapeutic strategy for Parkinson's disease. Molecular Therapy 2010, 18:1536-1544.
3. Cartier N., Hacein-Bey-Abina S., Bartholomae C.C., Veres G., Schmidt M., Kutschera I., Vidaud M., Abel U., Dal-Cortivo L., Caccavelli L., Mahlaoui N., Kiermer V., Mittelstaedt D., Bellesme C., Lahlou N., Lefrere F., Blanche S., Audit M., Payen E., Leboulch P., l'Homme B., Bougneres P., von K.C., Fischer A., Cavazzana-Calvo M., Aubourg P. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 2009, 326:818-823.
4. Choi Y., Yoon Y.W., Na H.S., Kim S.H., Chung J.M. Behavioral signs of ongoing pain and cold allodynia in a rat model of neuropathic pain. Pain 1994, 59:369-376.
5. Czechowicz A., Kraft D., Weissman I.L., Bhattacharya D. Efficient transplantation via antibody-based clearance of hematopoietic stem cell niches. Science 2007, 318:1296-1299.
6. Dauer W., Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003, 39:889-909.
7. Dunnett S.B., Carter R.J., Watts C., Torres E.M., Mahal A., Mangiarini L., Bates G., Morton A.J. Striatal transplantation in a transgenic mouse model of Huntington's disease. Experimental Neurology 1998, 154:31-40.
8. Fearnley J.M., Lees A.J. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991, 114(Pt 5):2283-2301.
9. Fjord-Larsen L., Johansen J.L., Kusk P., Tornoe J., Gronborg M., Rosenblad C., Wahlberg L.U. Efficient in vivo protection of nigral dopaminergic neurons by lentiviral gene transfer of a modified neurturin construct. Experimental Neurology 2005, 195:49-60.
10. Hacein-Bey-Abina S., Hauer J., Lim A., Picard C., Wang G.P., Berry C.C., Martinache C., Rieux-Laucat F., Latour S., Belohradsky B.H., Leiva L., Sorensen R., Debre M., Casanova J.L., Blanche S., Durandy A., Bushman F.D., Fischer A., Cavazzana-Calvo M. Efficacy of gene therapy for X-linked severe combined immunodeficiency. New England Journal of Medicine 2010, 363:355-364.
11. He W., Qiang M., Ma W., Valente A.J., Quinones M.P., Wang W., Reddick R.L., Xiao Q., Ahuja S.S., Clark R.A., Freeman G.L., Li S. Development of a synthetic promoter for macrophage gene therapy. Human Gene Therapy 2006, 17:949-959.
12. Hickey W.F., Kimura H. Perivascular microglial cells of the CNS are bone marrow-derived and present antigen in vivo. Science 1988, 239:290-292.
13. Hoane M.R., Gulwadi A.G., Morrison S., Hovanesian G., Lindner M.D., Tao W. Differential in vivo effects of neurturin and glial cell-line-derived neurotrophic factor. Experimental Neurology 1999, 160:235-243.
14. Kordower J.H., Herzog C.D., Dass B., Bakay R.A., Stansell J., Gasmi M., Bartus R.T. Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys. Annals of Neurology 2006, 60:706-715.
15. Kotzbauer P.T., Lampe P.A., Heuckeroth R.O., Golden J.P., Creedon D.J., Johnson E.M., Milbrandt J. Neurturin, a relative of glial-cell-line-derived neurotrophic factor. Nature 1996, 384:467-470.
16. Kreutzberg G.W. Microglia: a sensor for pathological events in the CNS. Trends in Neurosciences 1996, 19:312-318.
17. (-/-) mice. Gene Therapy 2011, 18:835-841.
18. Ling E.A., Wong W.C. The origin and nature of ramified and amoeboid microglia: a historical review and current concepts. Glia 1993, 7:9-18.
19. McGeer P.L., Itagaki S., Akiyama H., McGeer E.G. Rate of cell death in parkinsonism indicates active neuropathological process. Annals of Neurology 1988, 24:574-576.
20. Ramaswamy S., Soderstrom K.E., Kordower J.H. Trophic factors therapy in Parkinson's disease. Progress in Brain Research 2009, 175:201-216.
21. Rodriguez M., varez-Erviti L., Blesa F.J., Rodriguez-Oroz M.C., Arina A., Melero I., Ramos L.I., Obeso J.A. Bone-marrow-derived cell differentiation into microglia: a study in a progressive mouse model of Parkinson's disease. Neurobiology of Disease 2007, 28:316-325.
22. Salvatore M.F., Ai Y., Fischer B., Zhang A.M., Grondin R.C., Zhang Z., Gerhardt G.A., Gash D.M. Point source concentration of GDNF may explain failure of phase II clinical trial. Experimental Neurology 2006, 202:497-505.
23. Straathof K.C., Rao K., Eyrich M., Hale G., Bird P., Berrie E., Brown L., Adams S., Schlegel P.G., Goulden N., Gaspar H.B., Gennery A.R., Landais P., Davies E.G., Brenner M.K., Veys P.A., Amrolia P.J. Haemopoietic stem-cell transplantation with antibody-based minimal-intensity conditioning: a phase 1/2 study. Lancet 2009, 374:912-920.